YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
85 hedge funds and large institutions have $95.4M invested in Y-mAbs Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
85
Holders Change
-6
Holders Change %
-6.59%
% of All Funds
1.36%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
32
Reduced
27
Closed
19
Calls
$50K
Puts
$2K
Net Calls
+$48K
Net Calls Change
-$44K
Top Buyers
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$2.15M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.62M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.61M |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
+$1.15M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.01M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.28M |
| 2 |
Millennium Management
New York
|
-$2.53M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.95M |
| 4 |
BlackRock
New York
|
-$1.09M |
| 5 |
E
Ergoteles
New York
|
-$936K |
